​

Lexicon Pharmaceuticals (LXRX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

LXRX Stock Forecast

Lexicon Pharmaceuticals (LXRX) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $6.00, with a high of $6.00 and a low of $6.00. This represents a 622.89% increase from the last price of $0.83.

- $1 $2 $3 $4 $5 $6 High: $6 Avg: $6 Low: $6 Last Closed Price: $0.83

LXRX Stock Rating

Lexicon Pharmaceuticals stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 4 Strong Sell Sell Hold Buy Strong Buy

LXRX Forecast vs Benchmarks

TypeNameUpside
StockLexicon Pharmaceuticals622.89%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$6.00
Last Closing Price$0.83$0.83$0.83
Upside/Downside--622.89%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 25222--6
Dec, 24222--6
Nov, 24323--8
Oct, 24323--8
Sep, 24323--8
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 18, 2024Roanna RuizLeerink Partners$6.00$2.01198.51%622.89%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Oct 23, 2024H.C. WainwrightBuyBuyhold
Oct 18, 2024Leerink PartnersOutperformOutperformhold
Oct 17, 2024Piper SandlerOverweightOverweighthold
Sep 27, 2024H.C. WainwrightBuyBuyhold
Sep 03, 2024H.C. WainwrightBuyBuyhold
Aug 02, 2024H.C. WainwrightBuyBuyhold
Jun 17, 2024H.C. WainwrightBuyinitialise
May 31, 2024Piper SandlerOverweightOverweighthold
Jul 01, 2022CitigroupBuyBuyhold

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.63$-0.61$-0.62$-0.79-----
Avg Forecast$-0.74$-0.61$-0.56$-0.80$-0.68$-0.46$-0.41$-0.30$-0.08
High Forecast$-1.07$-0.87$-1.71$-0.81$-0.76$-0.67$-0.68$-0.39$-0.22
Low Forecast$-0.52$-0.43$-0.15$-0.78$-0.59$-0.32$-0.26$-0.18$-0.02
Surprise %-14.86%-10.71%-1.25%-----

Revenue Forecast

$0 $100M $200M $300M $400M $500M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$24.00M$298.00K$139.00K$1.20M-----
Avg Forecast$156.75M$194.67K$137.00K$1.75M$11.13M$13.33M$26.92M$94.86M$188.72M
High Forecast$121.03M$150.31K$60.61K$1.62M$5.59M$5.45M$26.92M$37.10M$73.80M
Low Forecast$210.41M$261.29K$352.10K$1.87M$26.90M$29.25M$26.92M$235.47M$468.45M
Surprise %-84.69%53.08%1.46%-31.26%-----

Net Income Forecast

$-250M $-200M $-150M $-100M $-50M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-70.18M$-88.27M$-103.13M$-175.61M-----
Avg Forecast$-163.56M$-96.45M$-97.36M$-177.12M$-149.02M$-109.19M$-104.28M$-62.60M$-16.95M
High Forecast$-236.33M$-115.74M$-116.83M$-212.54M$-168.35M$-147.86M$-150.62M$-85.46M$-49.62M
Low Forecast$-115.10M$-77.16M$-77.89M$-141.70M$-129.68M$-70.52M$-57.93M$-39.75M$-3.53M
Surprise %-57.09%-8.48%5.92%-0.85%-----

LXRX Forecast FAQ

Is Lexicon Pharmaceuticals stock a buy?

Lexicon Pharmaceuticals stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Lexicon Pharmaceuticals is a favorable investment for most analysts.

What is Lexicon Pharmaceuticals's price target?

Lexicon Pharmaceuticals's price target, set by 4 Wall Street analysts, averages $6 over the next 12 months. The price target range spans from $6 at the low end to $6 at the high end, suggesting a potential 622.89% change from the previous close price of $0.83.

How does Lexicon Pharmaceuticals stock forecast compare to the average forecast of its sector, industry, and investment themes?

Lexicon Pharmaceuticals stock forecast shows a 622.89% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and outperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Lexicon Pharmaceuticals over the past three months?

  • January 2025: 33.33% Strong Buy, 33.33% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 33.33% Strong Buy, 33.33% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 37.50% Strong Buy, 25.00% Buy, 37.50% Hold, 0% Sell, 0% Strong Sell.

What is Lexicon Pharmaceuticals’s EPS forecast?

Lexicon Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December is -0.68 for 2024, a -13.92% decrease from the reported $-0.79 in 2023. The prediction for 2025 is $-0.46, $-0.41 for 2026, $-0.3 for 2027, and $-0.08 for 2028.

What is Lexicon Pharmaceuticals’s revenue forecast?

Lexicon Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December is $11.13M for 2024, a 824.52% increase from the reported $1.2M in 2023. The forecast for 2025 is $13.33M, $26.92M for 2026, $94.86M for 2027, and $188.72M for 2028.

What is Lexicon Pharmaceuticals’s net income forecast?

For its fiscal year ending in December, Lexicon Pharmaceuticals's average annual net income forecast is $-149M for 2024, reflecting a -15.14% decrease from the reported $-176M in 2023. The projection for 2025 is $-109M, $-104M for 2026, $-62.603M for 2027, and $-16.953M for 2028.